Teleflex (NYSE:TFX) Stock Price Target Raised at Wells Fargo & Company

Teleflex (NYSE:TFX) had its target price lifted by Wells Fargo & Company from $138.00 to $167.00 in a report issued on Friday, Benzinga reports. The firm currently has an “equal weight” rating on the medical technology company’s stock. Wells Fargo & Company‘s target price would suggest a potential upside of 11.12% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. Needham & Company LLC boosted their target price on shares of Teleflex from $159.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Truist Financial cut their target price on shares of Teleflex from $150.00 to $142.00 and set a “hold” rating for the company in a research note on Wednesday, October 14th. Wall Street Zen upgraded shares of Teleflex from a “sell” rating to a “hold” rating in a report on Sunday, August 9th. UBS Group boosted their price target on shares of Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Finally, Mizuho set a $160.00 price objective on shares of Teleflex in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $158.80.

Teleflex Stock Down 1.2%

NYSE TFX opened at $150.29 on Friday. The stock’s 50 day moving average is $131.88 and its 200 day moving average is $125.84. The company has a current ratio of 2.60, a quick ratio of 2.12 and a debt-to-equity ratio of 0.94. Teleflex has a 12 month low of $100.18 and a 12 month high of $156.67. The stock has a market cap of $6.37 billion, a PE ratio of -6.37, a P/E/G ratio of 1.01 and a beta of 0.85.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, November 5th. The medical technology company reported $2.63 earnings per share for the quarter, topping the consensus estimate of $1.90 by $0.73. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%. The business had revenue of $567.80 million during the quarter, compared to the consensus estimate of $565.52 million. During the same period in the prior year, the company posted $3.67 EPS. The firm’s revenue for the quarter was up .1% compared to the same quarter last year. Research analysts predict that Teleflex will post 7.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Teleflex

Hedge funds have recently bought and sold shares of the business. Kelleher Financial Advisors bought a new position in shares of Teleflex in the 2nd quarter valued at about $25,000. Root Financial Partners LLC bought a new stake in Teleflex during the third quarter worth approximately $27,000. Next Level Wealth Planning LLC purchased a new stake in Teleflex during the third quarter valued at approximately $38,000. Heritage Family Offices LLP purchased a new stake in Teleflex during the third quarter valued at approximately $39,000. Finally, Allworth Financial LP bought a new stake in shares of Teleflex in the 2nd quarter valued at approximately $44,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Trending Headlines about Teleflex

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex reported third-quarter adjusted EPS of $2.63, above analyst estimates of about $1.90–$1.92. Revenue of $567.8 million also modestly exceeded expectations. Teleflex third-quarter results and outlook
• Positive Sentiment: Mizuho raised its price target on TFX to $160, potentially signaling improved analyst expectations for the shares. Mizuho price target update
• Neutral Sentiment: The company declared a quarterly dividend of $0.34 per share, payable December 31 to shareholders of record November 16. Teleflex dividend announcement
• Neutral Sentiment: A tranche update was reported for Teleflex’s previously announced share-repurchase plan, but the provided item does not specify the size or details of the update. Share buyback plan update
• Negative Sentiment: Despite the earnings beat, revenue grew only 0.2% year over year, while adjusted EPS declined from $3.67 a year earlier. This points to limited underlying growth and may temper the positive reaction to the quarter.

Teleflex Company Profile

Teleflex Incorporated is a global medical technology company that develops, manufactures and markets specialty medical devices. Its products are designed to support healthcare professionals in critical care and procedural settings, including vascular access, interventional cardiology and radiology, anesthesia, respiratory care, emergency medicine, surgical applications and urology.

The company’s portfolio includes catheters, access and closure devices, airway-management products, surgical instruments, pain-management devices and other technologies used in hospitals and outpatient facilities.